دورية أكاديمية
أعرض في EDS

Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction.

التفاصيل البيبلوغرافية
العنوان: Priority of lymph node dissection for advanced esophagogastric junction adenocarcinoma with the tumor center located below the esophagogastric junction.
المؤلفون: Cai MZ; Department of General Surgery, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China., Lv CB, Cai LS, Chen QX
المصدر: Medicine [Medicine (Baltimore)] 2019 Dec; Vol. 98 (51), pp. e18451.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, Md : Lippincott Williams & Wilkins
مواضيع طبية MeSH: Esophagogastric Junction* , Lymph Node Excision*, Adenocarcinoma/*surgery , Stomach Neoplasms/*surgery, Aged ; Female ; Humans ; Male ; Middle Aged ; Quality Improvement ; Retrospective Studies
مستخلص: To clarify the priority of lymph node dissection (LND) in advanced Siewert type II and III AEG, in which the center of the tumor is located below the esophagogastric junction (EGJ).Data in 395 patients with advanced Siewert type II or III AEG was analyzed retrospectively. The index of estimated benefit from LND (IEBLD) was used to evaluate the efficacy of LND for each nodal station.The mean number of dissected LNs did not differ significantly between patients with type II and III AEG, nor did the mean number of retrieved LNs at each station significantly differ between the 2 groups. According to the IEBLD, the dissection of parahiatal LNs (No.19 and 20) and LNs along the distal portion of the stomach (No.5, 6, and 12a) seemed unlikely to be beneficial, whereas the dissection of Nos.1-3, 7, 9 and 11p yielded high therapeutic benefit (IEBLD>3.0) in both groups. The IEBLDs of No.4d, 8a, and 10 were much higher in type III than in type II AEG cases. No.10 LND may improve survival for type III AEG cases (IEBLD = 2.9), especially for subgroups with primary tumors invading the serosa layer, undifferentiated cancers, macroscopic type 3-4 tumors and tumors ≥50 mm in size (all IEBLDs > 4.0).For advanced AEG located below the EGJ, the dissection of paracardial LNs, lesser curvature LNs, and LNs around the celiac axis would promote higher survival benefits regardless of the Siewert subtype. Patients with type III AEG, especially those with serosa-invasive tumors, undifferentiated tumors, macroscopic type 3-4 tumors and tumors ≥50 mm in size may obtain relatively higher survival benefits from No. 10 lymphadenectomy.
References: Ann Surg Oncol. 2015 Feb;22(2):597-603. (PMID: 25190126)
Eur J Surg Oncol. 2017 Dec;43(12):2333-2340. (PMID: 28928013)
Br J Surg. 2013 Jan;100(2):261-6. (PMID: 23180514)
Gastric Cancer. 2016 Jan;19(1):143-9. (PMID: 25414051)
Med Oncol. 2014 Aug;31(8):116. (PMID: 25023054)
Anticancer Res. 2016 May;36(5):2323-9. (PMID: 27127139)
Medicine (Baltimore). 2014 Nov;93(25):e158. (PMID: 25437029)
Br J Surg. 1995 Mar;82(3):346-51. (PMID: 7796005)
Ann Thorac Surg. 2015 Jul;100(1):263-9. (PMID: 25980597)
Medicine (Baltimore). 2016 May;95(21):e3473. (PMID: 27227913)
Br J Surg. 1998 Nov;85(11):1457-9. (PMID: 9823902)
Gastric Cancer. 2013 Oct;16(4):590-5. (PMID: 23179369)
Semin Radiat Oncol. 2013 Jan;23(1):3-9. (PMID: 23207041)
Ann Surg Oncol. 2009 May;16(5):1304-9. (PMID: 19241107)
Gastric Cancer. 2014 Mar 22;:null. (PMID: 24658651)
J Thorac Oncol. 2017 Jan;12(1):36-42. (PMID: 27810391)
Gastric Cancer. 2017 Jan;20(1):1-19. (PMID: 27342689)
Gastric Cancer. 2011 Jun;14(2):101-12. (PMID: 21573743)
Gastric Cancer. 2010 Jun;13(2):63-73. (PMID: 20602191)
Gastric Cancer. 2013 Jul;16(3):301-8. (PMID: 22895616)
Gastric Cancer. 2017 Mar;20(Suppl 1):69-83. (PMID: 27796514)
J Clin Oncol. 2011 Nov 10;29(32):4338-9; author reply 4340-2. (PMID: 22010017)
World J Surg Oncol. 2013 Jul 13;11:155. (PMID: 23849250)
Ann Surg. 2000 Sep;232(3):353-61. (PMID: 10973385)
Ann Surg Oncol. 2013 Dec;20(13):4252-9. (PMID: 23943020)
Ann Surg Oncol. 2012 Feb;19(2):677-83. (PMID: 21822549)
Gastric Cancer. 2013 Oct;16(4):454-6. (PMID: 23417699)
Updates Surg. 2017 Sep;69(3):319-325. (PMID: 28303519)
Ann Surg. 2011 Aug;254(2):274-80. (PMID: 21772128)
تواريخ الأحداث: Date Created: 20191222 Date Completed: 20200106 Latest Revision: 20200202
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC6940055
DOI: 10.1097/MD.0000000000018451
PMID: 31861019
قاعدة البيانات: MEDLINE
الوصف
تدمد:1536-5964
DOI:10.1097/MD.0000000000018451